139481-44-0

Basic information

• Product Name: Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate
• Synonyms: 1H-BENZIMIDAZOLE-7-CARBOXYLICACID, 1-[(2'-CYANO[1,1'-BIPHENYL]-4-YL)METHYL]-2-ETHOXY-METHYLESTER;1-(2-cyanobiphenyl-4-yl-methyl)- 2-ethoxybenzimidazole-7-carboxylic acid ethyl ester;Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate;Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl)Methyl)-2-ethoxy-1H-benzo[d]iMidazole-7-carboxylate;1-[(2'-Cyano-1,1'-biphenyl-4-yl)Methyl]-2-ethoxy-7-benziMidazolecarboxylic Acid Methyl Ester;3-[(2'-Cyanobiphenyl-4-yl)Methyl]-2-ethoxy-3H-benziMidazole-4-carboxylic Acid Methyl Ester;Methyl 1-[(2'-Cyanobiphenyl-4-yl)Methyl]-2-ethoxybenziMidazole-7-carbo;Methyl 1-((2'-cyanobiphenyl-4-yl)Methyl)-2-ethoxy-1H-benzo[d]iMidazole-7-carboxylate
• CAS NO: 139481-44-0
• Molecular Formula: C₂₅H₂₁N₃O₃
• Molecular Weight: 411.45
• EINECS: 1806241-263-5
• Product Categories: Candesartan;Intermediates;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 139481-44-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 168 °C
• Boiling Point: 630.416 °C at 760 mmHg
• Flash Point: 335.064 °C
• Appearance: /
• Density: 1.205 g/cm³
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly, Sonicated)
• CAS DataBase Reference: Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate(139481-44-0)
• EPA Substance Registry System: Methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate(139481-44-0)

Safety Data

• Hazardous Substances Data: 139481-44-0(Hazardous Substances Data)

Usage

Chemical Properties

Pale Yellow Solid

Uses

Intermediate in the synthesis of angiotensin II receptor antagonist.

Upstream product

• 150058-27-8 2-ethoxy-1H-benzimidazole-7-carboxylic acid methyl ester 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 139481-38-2 methyl 2-amino>-3-nitrobenzoate 
• 139481-28-0 methyl 2-<<2'-cyanobiphenyl-4-yl)methyl>amino>-3-nitrobenzoate 
• 856414-36-3 2-Azidocarbonyl-3-nitro-benzoic acid methyl ester 
• 57113-90-3 methyl 2-(N-tert-butoxycarbonylamino)-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 73833-13-3 acid chloride of 1-methylhydrogen-3-nitrophthalate 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 78-09-1 orthocarbonic acid tetraethyl ester 
• 136304-78-4 methyl 3-amino-2-[[(2'-cyanobiphenyl-4-yl)methyl]amino]benzoate 

Downstream Products

• 139481-72-4 2-Ethoxy-1-[[2'-(N-triphenylmethyltetrazol-5-yl)-biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid 
• 147403-52-9 methyl 2-ethoxy-1-((2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]-imidazole-7-carboxylate 
• 632322-62-4 2-ethoxy-1-[(2'-cyanobiphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylicacid-1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester 
• 147404-76-0 methyl 1-[(2'-carbamoylbiphenyl-4-yl)methyl]-2-ethoxybenzimidazole-7-carboxylate 
• 1397836-49-5 1-[(2'-(N'-hydroxycarbamimidoyl)[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-1,3-benzodiazole-7-carboxylic acid 
• 147404-82-8 methyl 2-ethoxy-1-[[2'-(ethoxycarbonyloxy-carbamimidoyl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate 
• 147403-65-4 methyl 2-ethoxy-1-((2′-(N′-hydroxycarbamimidoyl)-biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 
• 147403-52-9 methyl 2-ethoxy-1-[[2’-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate 
• 1675221-59-6 C₂₅H₂₂N₂O₅ 
• 1449029-80-4 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(N'-{[(4-nitrophenoxy)carbonyl]oxy}carbamimidoyl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate 
• 1449029-78-0 (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl 2-ethoxy-1-[(2'-{N'-[(ethoxycarbonyl)oxy]carbamimidoyl}-biphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylate 

Relevant articles and documents

A method for preparing [...] (by machine translation)

The invention belongs to the field of drug synthesis; a [...] preparation method, characterized in that comprises the following steps: a [...] preparation method, characterized in that includes: 1) compound 5 under the alkaline condition and act on the hydroxylamine hydrochloride, heating the reaction to produce compound 6; 2) compound 6 in three ethylene diamine with carbonyl diimidazole role, reaction to produce compound 4; 3) compound 4 in the hydrolysis reaction under alkaline conditions, obtain arab league qi shatan thick; 4) coarse [...] refined [...]. The invention states arab league qi shatan preparation method has the short reaction time, high purity of the product, the advantage of high yield, it is suitable for large-scale industrial production. (by machine translation)

PROCESS FOR PREPARATION OF CANDESARTAN CILEXETIL

There was provided a process for preparing candesartan cilexetil, the said process comprises hydrogenating a solution of trityl candesartan cilexetil in an alcohol with hydrogen in the presence of a palladium catalyst. Mixture of toluene and methanol was added to 1-(Cyclohexyloxy carbonyloxy)ethyl-2-ethoxy-1-[[2'-(N-triphenylmethyltetrazole-5-yl)biphenyl-4-yl] methyl]benzimidazole-7-carboxylate and hydrogenated at room temperature with hydrogen at atmospheric pressure in the presence of palladium on carbon until the hydrogen uptake was ceased. Filtered over celite bed, washed the bed with a mixture of toluene and methanol, filtrate was collected and concentrated. Co- distilled with acetonitrile, acetonitrile was added, stirred at room temperature, cooled to 0°C. stirred, filtered, washed with chilled acetonitrile and dried to get candesartan cilexetil.

CRYSTAL AND PROCESS FOR PRODUCING THE SAME

A process for producing crystals of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimdazole-7-carboxylic acid (compound (I)), characterized by dissolving or suspending the compound (I) or a salt thereof in a solvent comprising an aprotic polar solvent and crystallizing it. By the process, the contaminants which are contained in the compound (I) or its salt and are difficult to remove, such as tin compounds, analogues of the compound (I), and a residual organic solvent, can be easily removed. Crystals of the compound (I) can be efficiently and easily mass-produced in high yield on an industrial scale.